Primary Treatment: Treatment · No Placebo Group · N/A
Screening: ~3 weeks
Reporting: assessed at week 0 and week 11
Who is running the clinical trial?
Stanford UniversityLead Sponsor
2,148 Previous Clinical Trials
35,678,934 Total Patients Enrolled
96 Trials studying Depression
92,525 Patients Enrolled for Depression
Andrea Goldstein-Piekarski, PhDPrincipal Investigator - Stanford University
2 Previous Clinical Trials
199 Total Patients Enrolled
Age 18 - 65 · All Participants · 6 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:
Many people complain of not getting enough sleep, or of poor sleep quality, for at least three months
People who complain of depression (score of 14 or higher on the BDI questionnaire) and don't seem to be at risk for suicide are assessed with the CSSRS tool.
She is fluent in both English and Spanish.
significantly improved mean reductions in pain intensity from baseline to week 4
Drinking ≤ 3 cups of coffee or other caffeinated drinks prior to lunch every day for at least 3 weeks before treatment significantly improved pain intensity reductions from baseline to week 4.
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.